A recent study published in Nature Communications evaluated the efficacy and cost-effectiveness of combining long-acting injectable antiretrovirals lenacapavir and cabotegravir for HIV treatment in African settings. This regimen has the potential to improve adherence, viral suppression, and reduce transmission, marking a transformative advancement in managing HIV epidemics on the continent.